Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Ulcerative colitis surgery

Introduction

Overview

Overview

Because ulcerative colitis (UC) is confined to the colon and rectum, proctocolectomy removes the target organ and cures the intestinal disease.[1]

Indications for surgery fall into three tiers: emergent, urgent, and elective. Emergent indications are perforation, uncontrolled hemorrhage, and refractory toxic megacolon. The main urgent indication is acute severe UC (ASUC) that fails intravenous corticosteroids or medical rescue therapy. Elective indications include medically refractory disease, intolerable drug toxicity, and dysplasia or colorectal cancer that cannot be managed endoscopically.[2][3]

For most patients who want to avoid a permanent stoma, restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) is the procedure of choice. Total proctocolectomy with end ileostomy remains a curative alternative with equivalent quality of life.[1] The most common long-term complication of IPAA is pouchitis, which is managed along a chronicity spectrum.[4]

Surgery

Surgery

Indications

Urgency Indication Comment
Emergent Colonic perforation
Uncontrolled or severe colonic hemorrhage
Toxic megacolon unresponsive to medical therapy and decompression
Multiorgan dysfunction 		Absolute indications. The first-stage operation is subtotal colectomy with end ileostomy.[2][3]
Urgent ASUC with inadequate response to IV corticosteroids by day 3–5, or failure of salvage infliximab or cyclosporine Obtain surgical consultation by day 3 in corticosteroid non-responders. Delaying colectomy is associated with more postoperative complications.[2]
Elective Medically refractory chronic UC (failure of, or dependence on, corticosteroids, biologics, or small molecules)
Intolerable medication adverse effects
Dysplasia not amenable to endoscopic resection, or colorectal carcinoma
Selected patients by preference, after shared decision-making 		Timing and procedure are individualized to nutrition, immunosuppression, and patient goals.[2][5]

In ASUC that fails IV corticosteroids or infliximab induction, the ACG states there are insufficient data to routinely recommend tofacitinib or upadacitinib as additional rescue before colectomy. A third sequential rescue agent carries a high risk of severe immunosuppression and complications.[2]

Surgical Options

Procedure Key features Preferred in
Restorative proctocolectomy with IPAA The colon and rectum are removed and an ileal reservoir (usually a J-pouch) is anastomosed to the anal canal. Morbidity is 19–27% and mortality is <0.5%. Quality of life approaches that of the general population. A stapled anastomosis is generally preferred over mucosectomy with handsewn anastomosis for better function.[1] Most patients who want to preserve transanal defecation
Total proctocolectomy with end ileostomy Curative and non-restorative. Quality of life is equivalent to IPAA.[1] Fecal incontinence or poor sphincter function, significant comorbidity, inability to undergo pouch surveillance, or patient preference[1]
Subtotal (total abdominal) colectomy with end ileostomy The colon is removed and the rectal stump left in place. Pelvic dissection is deferred until the patient is stable and nutritionally optimized.[1] Emergent or urgent surgery. It is the first stage of staged IPAA.
Total abdominal colectomy with ileorectal anastomosis (IRA) Weak recommendation (ASCRS grade 2B). Function is good and fertility is preserved because pelvic dissection is avoided. Disease and cancer risk remain in the rectum: completion proctectomy for refractory proctitis is needed in about 10%, 24–27%, and 40% of patients at 5, 10, and 20 years.[1] Highly selected patients with a relatively spared, compliant rectum
Continent ileostomy (Kock pouch) High rates of dysfunction, revision, and excision limit its use.[1] Patients in whom IPAA is contraindicated or has failed, who prefer it to a conventional ileostomy

Staging of Restorative Proctocolectomy

IPAA is performed in one, two, modified two, or three stages. The choice depends on acuity, nutritional status, anemia, and immunosuppression.[1][6]

  • Three-stage: (1) subtotal colectomy with end ileostomy; (2) completion proctectomy, IPAA, and diverting loop ileostomy; (3) ileostomy closure. Preferred in ASUC, malnutrition, anemia, or heavy immunosuppression, to allow recovery and limit pelvic sepsis.
  • Conventional two-stage: total proctocolectomy with IPAA and diverting loop ileostomy, followed by ileostomy closure.
  • Modified two-stage: subtotal colectomy with end ileostomy, followed by completion proctectomy and IPAA without a diverting loop ileostomy. Compared with conventional two-stage surgery, it is not associated with more anastomotic leak, pelvic sepsis, or pouch failure, and length of stay is shorter.[1]
  • Single-stage restorative proctocolectomy should be avoided in patients receiving biologic therapy.[1]

When expertise is available, laparoscopic or robotic approaches are preferred. Low institutional case volume independently predicts pouch failure, so IPAA should be performed at high-volume centers.[1][5]

Perioperative Optimization

  • Nutrition: Malnutrition predicts higher in-hospital mortality, longer stay, and more infections. Markers include weight loss >10–15% over 6 months, BMI <18.5 kg/m², or albumin <30 g/L. When feasible, optimize with enteral or parenteral nutrition before colectomy.[2]
  • Corticosteroids: Prolonged preoperative corticosteroid exposure increases postoperative infectious complications. This is a key reason for staged surgery.[2][1]
  • Biologics and small molecules: Infliximab and cyclosporine do not increase postoperative complications, and surgery should not be deferred because of recent exposure. In UC, preoperative anti-TNF therapy has not been associated with more postoperative infectious complications. Perioperative vedolizumab data show no clear increase in risk. Robust data on small molecules before colectomy are lacking.[2]
  • Infection: Exclude Clostridioides difficile infection and cytomegalovirus colitis in hospitalized patients before surgical decision-making.[2]

Pouchitis and Inflammatory Pouch Disorders

Before treating presumed pouchitis, confirm inflammation by pouchoscopy with biopsy. Exclude mimics: C. difficile, CMV, cuffitis, Crohn’s disease of the pouch, irritable pouch syndrome, and structural complications such as anastomotic leak or stricture.[4][7] All AGA recommendations below are conditional and based on low or very low certainty evidence.[4]

Phenotype Suggested management
Intermittent (acute) pouchitis Ciprofloxacin or metronidazole for 2–4 weeks. Combination antibiotics for single-agent non-response. Oral vancomycin is an alternative for intolerance, allergy, or refractory cases.[4]
Recurrent, antibiotic-responsive Multi-strain probiotic (De Simone formulation) for prevention of recurrence.[4]
Chronic antibiotic-dependent Chronic or cyclical low-dose antibiotics (e.g., ciprofloxacin 500 mg daily or 250 mg twice daily with intermittent gaps, or rotating agents). Advanced immunosuppressive therapy is an alternative for patients intolerant of, or concerned about, long-term antibiotics.[4]
Chronic antibiotic-refractory / Crohn’s-like disease of the pouch Advanced immunosuppressive therapy. Vedolizumab has the best evidence and is the only EMA-approved agent for chronic pouchitis. Other options are TNF antagonists, ustekinumab, risankizumab, ozanimod, tofacitinib, and upadacitinib (very low certainty). Agents used before colectomy may be reconsidered.[4]

Cuffitis (inflammation of the retained rectal cuff) is treated with topical mesalamine suppositories or enemas, with topical corticosteroids as second line.[7]

Effect of Colectomy on Extraintestinal Manifestations

  • Extraintestinal manifestations that parallel intestinal inflammatory activity may improve after colectomy. These include peripheral arthropathy, erythema nodosum, and episcleritis.[8]
  • Primary sclerosing cholangitis (PSC) runs a course independent of colonic disease activity and is not cured by colectomy.[8] Pyoderma gangrenosum generally does not respond to colectomy.[8]
  • In patients with an ileal pouch, PSC and other extraintestinal manifestations are associated with chronic pouchitis, and PSC with possible pouch neoplasia.[9]
  • Colectomy is not recommended for isolated extraintestinal manifestations. It may be weighed as part of a broader discussion of elective surgery.[8]

Areas of Uncertainty

  • Two- vs three-stage IPAA: Some multicenter data favor three stages in immunosuppressed patients, while single-center series show no difference. Individualize based on disease severity, nutrition, anemia, and surgeon experience.[1]
  • JAK inhibitors and S1P modulators as additional ASUC rescue before colectomy are not established.[2]
  • Timing of colectomy in corticosteroid non-responders involves a trade-off between avoiding surgery and the risks of prolonged, sequential immunosuppression.[2]
  • Segmental colectomy vs total proctocolectomy for localized UC-associated neoplasia remains unresolved.
References

References

  1. ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons (2021). “The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis”. Dis Colon Rectum. 64 (7): 783–804. doi:10.1097/DCR.0000000000002037. PMID 33853087 Check |pmid= value (help).
  2. ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Rubin DT, Ananthakrishnan AN, Siegel CA, Barnes EL, Long MD (2025). “ACG Clinical Guideline Update: Ulcerative Colitis in Adults”. Am J Gastroenterol. 120 (6): 1187–1224.
  3. ↑ 3.0 3.1 Kaur M, Dalal RL, Shaffer S, Schwartz DA, Rubin DT (2020). “Inpatient Management of Inflammatory Bowel Disease-Related Complications”. Clin Gastroenterol Hepatol. 18 (6): 1346–1355.
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Barnes EL, Agrawal M, Syal G, et al.; AGA Clinical Guidelines Committee (2024). “AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders”. Gastroenterology. 166 (1). doi:10.1053/j.gastro.2023.10.015.
  5. ↑ 5.0 5.1 Le Berre C, Honap S, Peyrin-Biroulet L (2023). “Ulcerative colitis”. Lancet. 402 (10401): 571–584.
  6. ↑ Vieujean S, Jairath V, Peyrin-Biroulet L, Dubinsky M, Iacucci M, Magro F, Danese S (2025). “Understanding the therapeutic toolkit for inflammatory bowel disease”. Nat Rev Gastroenterol Hepatol. 22 (6): 371–394. doi:10.1038/s41575-024-01035-7.
  7. ↑ 7.0 7.1 Rabbenou W, Chang S (2021). “Medical treatment of pouchitis: a guide for the clinician”. Therap Adv Gastroenterol. 14: 17562848211023376. doi:10.1177/17562848211023376. PMID 34249146 Check |pmid= value (help).
  8. ↑ 8.0 8.1 8.2 8.3 Rogler G, Singh A, Kavanaugh A, Rubin DT (2021). “Extraintestinal Manifestations of Inflammatory Bowel Disease: Current Concepts, Treatment, and Implications for Disease Management”. Gastroenterology. 161 (4): 1118–1132. doi:10.1053/j.gastro.2021.07.042. PMID 34358489 Check |pmid= value (help).
  9. ↑ “Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients With Ileal Pouches: A Systematic Review”. Dis Colon Rectum. 2024. PMID 38411984 Check |pmid= value (help).

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Tarek Nafee, M.D. [3]